Pulmonary rehabilitation for COPD and other lung diseases
Concurrent treatment with ø-agonists and/or hormonal treatments and/or new therapies (e.g., spiriva) and/or concurrent treatment with supplementary oxygen6. Concurrent PR in disease management programs7. Place of delivery (e.g., home, inpatient, outpatient).8. Physician supervision9. Components of t...
| Main Authors: | , , , |
|---|---|
| Corporate Authors: | , |
| Format: | eBook |
| Language: | English |
| Published: |
Rockville, Maryland
AHRQ Technology Assessment Program
2006, November 21, 2006
|
| Series: | Technology assessment
|
| Subjects: | |
| Online Access: | |
| Collection: | National Center for Biotechnology Information - Collection details see MPG.ReNa |
| Summary: | Concurrent treatment with ø-agonists and/or hormonal treatments and/or new therapies (e.g., spiriva) and/or concurrent treatment with supplementary oxygen6. Concurrent PR in disease management programs7. Place of delivery (e.g., home, inpatient, outpatient).8. Physician supervision9. Components of the PR and whether components were individually tailored or generalized10. Persistence of benefits/harms over time11. Repeated course of PR. The overarching question of interest to CMS is: What is the evidence for safety and effectiveness of PR for patients e65 years old with COPD, asthma, bronchiectasis and other relevant conditions? CMS is also interested in a description of the outcomes measures reported in the studies, a summary of the evidence on complications, harms, and adverse events associated with PR that have been reported, and an assessment on whether conditions prevalent in the older Medicare population increase the risk for these events with PR. Specific factors of interest to CMS include:1. Internal and external validity of the studies (includes inclusion and exclusion criteria of the studies).2. Length of follow-up3. Intensity of treatment, number and frequency of sessions4. Patient characteristics (i.e., gender, comorbidity) and disease characteristics (i.e., disease severity). Age of patients and generalizability to Medicare population.5. The Center for Medicare and Medicaid Services (CMS) has requested a technology assessment through the Agency for Healthcare Research and Quality (AHRQ) on pulmonary rehabilitation (PR) primarily for COPD and conditions such as asthma, bronchiectasis, ventilator dependency, and other relevant respiratory illness. The objective is to address specific questions about safety and effectiveness of PR. There seems to be limited evidence on safety and effectiveness of PR for other conditions of interest, apart from COPD. Also, the evidence of PR effectiveness in the elderly has not been systematically evaluated. Specific components of PR and subgroups of patients eligible for PR are also of interest to CMS. |
|---|---|
| Item Description: | Title from PDF title page |
| Physical Description: | 1 PDF file (139 pages) illustrations |